Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 11, Issue 1, 2011, Pages 121-129

  Godman, Brian ^a,b,c   Sakshaug, Solveig ^d   Berg, Christian ^d   Wettermark, Björn ^b,e   Haycox, Alan ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^e STOCKHOLM COUNTY COUNCIL   (Sweden)

Author keywords

efficiency; generics; prescribing restrictions; reference pricing

Indexed keywords

ATORVASTATIN; ESOMEPRAZOLE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PRAVASTATIN; PROTON PUMP INHIBITOR; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; AUSTRIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG COST; DRUG UTILIZATION; FINLAND; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEALTH CARE POLICY; NORWAY; OUTCOME ASSESSMENT; POPULATION SIZE; PRESCRIPTION; REIMBURSEMENT;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; DRUGS, GENERIC; HEALTH CARE REFORM; HEALTH POLICY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSURANCE, PHARMACEUTICAL SERVICES; NORWAY; PHYSICIAN'S PRACTICE PATTERNS; PROTON PUMP INHIBITORS; REIMBURSEMENT MECHANISMS; RETROSPECTIVE STUDIES;

EID: 79952173201     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.10.87     Document Type: Article

References (55)

1. Godman B, Haycox A, Schwabe U et al. Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 26, 91-98 (2008).
2. Godman B, Bucsics A, Burkhardt T et al. Insight into recent reforms and initiatives in Austria; implications for key stakeholders. Expert Rev. Pharmacoeconomcis Outcomes Res. 8(4), 357-371 (2008).
3. Godman B, Burkhardt T, Bucsics A et al. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs; implications for the future. Expert Rev. Pharmacoeconomics Outcomes Res. 9(5), 475-484 (2009).
4. Sermet C, Andrieu V, Godman B et al. Ongoing pharmaceutical reforms in France; implications for key stakeholder groups. Appl. Health Econ. Health Policy 8, 7-24 (2010).
5. McGinn D, Godman B, Lonsdale J et al. Initiatives to enhance the efficiency of statin and proton pump inhibitor prescribing in the UK; impact and implications. Expert Rev. Pharmacoeconomics Outcomes Res. 10(1), 73-85 (2010).
6. Coma A, Zara C, Godman B et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan Region: impact and future direction. Expert Rev. Pharmacoeconomics Outcomes Res. 9(6), 569-581 (2009).
7. Hakonsen H, Horn A, Toverud EL. Price control as a strategy for pharmaceutical cost-containment - what has been achieved in Norway in the period 1994-2004? Health Policy 90, 277-285 (2009).
8. Fattore G, Jommi C. The last decade of Italian pharmaceutical policy - instability or consolidation? Pharmacoeconomics 26, 5-15 (2008).
9. Simoens S. Trends in generic prescribing and dispensing in Europe. Expert. Rev. Clin. Pharmacol. 1(4), 497-503 (2008).
10. Simoens S. International comparison of generic medicine prices. Curr. Med. Res. Opin. 23, 2647-2654 (2007). (Pubitemid 350146403)
11. Godman B, Schwabe U, Selke G, Wettermark B. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid lowering drugs. Pharmacoeconomics 27, 435-438 (2009).
12. Godman B, Shrank W, Wettermark B et al. Use of generics - a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals 3, 2470-2494 (2010).
13. McKee M, Stickler D, Martin-Moreno J. Protecting health in hard times - Europes health ministers exchange experiences on the impact of the economic crisis. BMJ 341, 681-682 (2010).
14. Aaserud M, Austvoll-Dahlgren A, Kösters JP et al. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Syst. Rev. 19(2), CD005979 (2006).
15. Wettermark B, Godman B, Andersson K et al. Recent national and regional drug reforms in Sweden - implications for pharmaceutical companies in Europe. Pharmacoeconomics 26, 537-550 (2008). (Pubitemid 351871549)
16. Godman B, Wettermark B, Hoffman M et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden; global relevance. Expert Rev. Pharmacoeconomcis Outcomes Res. 9(1), 65-83 (2009).
17. Sakshaug S, Furu K, Karlstad O et al. Switching statins in Norway after new reimbursement policy - a nationwide prescription study. Br. J. Clin. Pharmacol. 64, 476-481 (2007). (Pubitemid 47404299)
18. Wettermark B, Godman B, Neovius M et al. Initial effects of a reimbursement restriction to improve the cost- effectiveness of antihypertensive treatment. Health Policy 94, 221-229 (2010).
19. Godman B, Shrank W, Andersen M et al. Comparing policies to enhance the utilisation generics across Europe: changes seen and global implications. Expert Rev. Pharmacoeconomics Outcomes Res. 10(6), 707-722 (2010).
20. Martikainen J, Saastamoinen L, Korhonen M et al. Impact of restricted reimbursement on the use of statins in Finland - a register-based study. Med. Care 48, 761-766 (2010).
21. Garattini L, Motterlini N, Cornago D. Prices and distribution margins of in-patent drugs in pharmacy: a comparison in seven European countries. Health Policy 85, 305-313 (2008). (Pubitemid 351179534)
22. Garattini S, Bertele V, Godman B et al. Enhancing the rational use of new medicines across European healthcare systems - a position paper. Eur. J. Clin. Pharmacol. 64, 1137-1138 (2008).
23. Lee T, Emanuel E. Tier 4 drugs and the fraying of the social compact. N. Engl. J. Med. 359, 333-335 (2008).
24. Kjoenniksen I, Lindbaek M, Grannas A. Patients attitudes towards and experiences of generic drug substitution in Norway. Pharm. World Sci. 28, 284-289 (2006). (Pubitemid 44875826)
25. Hakonsen H, Eilertsen M, Borge H, Toverud EL. Generic substitution: additional challenge for adherence in hypertensive patients? Curr. Med. Res. Opin. 25, 2515-2521 (2009).
26. Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp F. Soft regulations in pharmaceutical policymaking - an overview of current approaches and their consequences. Appl. Health Econ. Health Policy 7, 1-11 (2009).
27. Fretheim A, Hvelsrud K, MacLennan G et al. The effects of mandatory prescribing of thiazides for newly treated, uncomplicated hypertension: interrupted time-series analysis. PLoS Med. 4(7) e232, 1178-1186 (2007).
28. Collins R, Armitage J, Parish S et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 with diabetes: a randomised placebo-controlled trial. Lancet 361, 2005-2016 (2003).
29. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology and the European Association for the Study of Diabetes. Eur. Heart J. 28, 88-136 (2007).
30. Josan K, Majumdar S, McAlister F. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ 178, 576-584 (2008). (Pubitemid 351414005)
31. Yang YY, Lewis J, Epstein S et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296, 2947-2953 (2006). (Pubitemid 46021498)
32. Gulmez S, Holm A, Frederiksen H et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch. Intern. Med. 167, 950-955 (2007). (Pubitemid 46762758)
33. Leonard J, Marshall JK, Moavvedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am. J. Gastroenterol. 102, 2047-2056 (2007). (Pubitemid 47301504)
34. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ 336, 2-3 (2008).
35. Katz MH. Failing the acid test - benefits of proton pump inhibitors may not justify the risks for many users. Arch. Intern. Med. 170, 747-748 (2010).
36. Howell M, Novack V, Grgurich P et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch. Intern. Med. 170, 784-790 (2010).
37. Rønning M, Blix HS, Harbø BT, Strøm H. Different versions of the anatomical therapeutic chemical classification system and the defined daily dose - are drug utilisation data comparable? Eur. J. Clin. Pharmacol. 56, 723-727 (2000). (Pubitemid 32204496)
38. Heikkilä R, Mäntyselkä P, Hartikainen-Herranen K, Ahonen R. Customers and physicians opinions of experiences with generic substitution during the first year in Finland. Health Policy 82, 366-374 (2007). (Pubitemid 46962790)
39. Andersson K, Jorgensem T, Carlsten A. Physicians opinions and experiences of the pharmaceutical benefits reform. Scand. J. Public Health 34, 654-659 (2006). (Pubitemid 44834981)
40. Anon. Good professional practice. ISDB Newsletter 20, 5-11 (2006).
41. Gilley J. Towards rational prescribing. BMJ 308, 731-732 (1994). (Pubitemid 24087427)
42. Walley T, Folin-Galo P, Stephens P, Van Ganse E. Trends in prescribing and utilisation of statins and other lipid lowering drugs across Europe 1997-2003. Br. J. Clin. Pharmacol. 60, 543-551 (2005). (Pubitemid 41532455)
43. Godman B, Buscics A, Burkhardt T et al. Initiatives to enhance renin-angiotensin prescribing efficiency in Austria; impact and implications for other countries. Expert Rev. Pharmacoeconomics Outcomes Res. 10(2), 199-207 (2010).
44. Wettermark B, Pehrsson A, Juhasz-Haverinen M et al. Financial incentives linked to self-assessment of prescribing patterns - a new approach for quality improvement of drug prescribing in primary care. Qual. Prim. Care 17, 179-189 (2009).
45. Bero L, Grilli R, Grimshaw J et al. Getting research into practice. BMJ 317, 465-468 (1998).
46. Fein O. Keep the single payer vision. Medical Care 48, 759-760 (2010).
47. Norman C, Zarrinkoub R, Hasselström J et al. Potential savings without compromising the quality of care. Int. J. Clin. Pract. 63, 1320-1326 (2009).
48. Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int. J. Clin. Pract. 62, 480-484 (2008). (Pubitemid 351197428)
49. Cramer JA, Benedict A, Muszabek N et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int. J. Clin. Pract. 62, 76-87 (2008). (Pubitemid 350294021)
50. Festoy H, Sveen K, Yu L-M et al. Norway - pharmaceutical pricing and reimbursement information http://ppri.oebig.at/Downloads/Results/ Norway-PPRI-2008.pdf
51. WHO. Guidelines for ATC classification and DDD assignment 2010. WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway www.whocc.no
52. WHO. Introduction to drug utilization research www.who.int/medicines/ areas/quality- safety/safety-efficacy/Drug%20 utilization%20research.pdf
53. WHO. DDD alterations from 1982-2010 www.whocc.no/atc-ddd-alterations- cumulative-/ddd-alterations/
54. Bank of Norway exchange rates www.norges-bank.no/webdav/stat/no/ valutakurser/valutakurser-aar-ukoplet.xls
55. WHO international nonproprietary names www.who.int/medicines/services/ inn/en/